Placebo; Dasatinib; Docetaxel; Prednisone
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00744497/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет, только мужчины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 1930 чел. во всех странах исследования.
- Плановая дата окончания (07.2015) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Состояние пациента (ECOG)0–2
- Стадияметастатическая (IV)
- Метастазы в головной мозгактивные — не включают
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 15
Критерии включения
- History of histologically diagnosed prostate cancer
- Evidence of metastatic disease by any 1 of the following: computed tomography scan, magnetic resonance imaging, bone scan, or skeletal survey
- Evidence of progression, as defined by 1 of the following: rising prostate specific antigen levels at least 1 week apart with the final value being >=2 ng/mL; progression of measurable nodal or visceral disease, with nodal lesions >=20 mm and visceral lesions measurable per response evaluation criteria for solid tumors (Response Evaluation in Solid Tumors, version 1); 2 or more lesions appearing on bone scan compared with previous scan; or local recurrence in the prostate or prostate bed
- Maintaining castrate status: Participants who have not undergone surgical orchiectomy should have received and continue on medical therapies, such as gonadotropin releasing hormone analogs, to maintain castrate levels of serum testosterone <=50 ng/dL
- Eastern Cooperative Oncology Group Performance Status of 0 to 2
- At least 4 weeks since an investigational agent prior to starting study therapy
- At least 8 weeks since radioisotope therapy prior to starting study therapy
- Recovery from any local therapy including surgery or radiation/radiotherapy for a minimum of 7 days prior to starting study therapy
- Required initial laboratory values: white blood cell count >=3,000/mm\^3; absolute neutrophil count >=1,500/mm\^3; platelet count >=100,000/mm\^3; creatinine level <=1.5*upper limit of normal (ULN); bilirubin <=ULN; aspartate aminotransferase <=2.5*ULN; alanine aminotransferase <=2.5*ULN.
Критерии невключения
- Symptomatic brain metastases or leptomeningeal metastases
- Clinically significant cardiovascular disease, including myocardial infarction; ventricular tachyarrhythmia within 6 months; prolonged QTc >450 msec; ejection fraction <40%; or major conduction abnormality, unless a cardiac pacemaker is present
- Pleural or pericardial effusion of any Common Terminology Criteria (CTC) grade
- Peripheral neuropathy CTC Grade >=2
- Currently active second malignancy other than nonmelanoma skin cancers. Participants are not considered to have a currently active malignancy if they have completed therapy and are now considered (by their physician) to be at less than 30% risk for relapse
- Uncontrolled intercurrent illness including ongoing or active infection, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- HIV infection-positive patients receiving combination antiretroviral therapy
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to the investigational agents
- Receipt of any other investigational agents for the treatment of prostate cancer
- Prior cytotoxic chemotherapy in the metastatic setting, with the exception of estramustine
- Patients may continue on a daily multivitamin but must discontinue all other herbal, alternative, and food supplements before enrollment
- Ketoconazole must be discontinued 4 weeks prior to starting study therapy
- Antiandrogens must be discontinued prior to starting study therapy. Patients with a history of response to an antiandrogen and subsequent progression while on that antiandrogen should be assessed for antiandrogen withdrawal response for 4 weeks. Observation for antiandrogen withdrawal response is not necessary for those who have never responded to antiandrogens
- Bisphosphonates must not be initiated within 28 days prior to starting study therapy
- QT prolonging agents strongly associated with torsade de pointes.
Источник: ClinicalTrials.gov, NCT00744497 · запись обновлена в реестре 17 октября 2016.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 6
- Overall Survival: Time From Randomization to Date of Death — From randomization to death or date of last contact (maximum reached: 45 months)
Цель исследования
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00744497 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.